Abstract: Provided herein are hemoglobin-based therapeutic agents useful for treating cancer, pharmaceutical composition including the same, and methods of use and preparation thereof.
Type:
Grant
Filed:
July 20, 2020
Date of Patent:
February 14, 2023
Assignee:
Cheer Global Limited
Inventors:
Sui-Yi Kwok, Norman Fung-Man Wai, Lan Zou
Abstract: This disclosure provides peptides that bind to LAG3 and can be used to block its interaction with other molecules such as MHC-II, FGL1, and ?-synuclein. These peptides, with their demonstrated activity and short half-life, can be used to activate cellular immunity while significantly reducing the potential for adverse events that is often associated with the antibody-based checkpoint inhibitors. The peptides can be used as stand-alone therapeutics or can be used as immune modulators in combination with other therapies.
Type:
Grant
Filed:
July 28, 2021
Date of Patent:
February 14, 2023
Assignee:
Leidos, Inc.
Inventors:
Gabriel M. Gutierrez, James Pannucci, Vinayaka Kotraiah, Timothy W. Phares, Cecilie D. Browne
Abstract: Disclosed are compositions and methods for treating inflammation including its end-stage sepsis and conditions mediated by inflammation such as liver apoptosis and cirrhosis, thrombocytopenia, hypoglycogenemia, hyperglycemia, and hypertriglyceridemia. In one aspect, the compositions and methods disclosed herein can also be used to enhance clearance of microbes from infected tissues, organs, or systems in a subject. Also disclosed herein are compositions and methods for reducing levels of stress responsible transcription factors and metabolic transcription factors in a cell in a subject with microbial, allergic, autoimmune, metabolic, and posttraumatic inflammation.
Type:
Grant
Filed:
May 29, 2020
Date of Patent:
February 7, 2023
Assignee:
VANDERBILT UNIVERSITY
Inventors:
Jack Jacek Hawiger, Jozef Zienkiewicz, Danya Liu
Abstract: The invention relates to a method for the cleavage of a solid phase-bound polypeptide from the solid phase, the method comprising contacting the solid phase, to which the polypeptide is bound, with a composition consisting essentially of trifluoroacetic acid and 1,2-ethanedithiol, at a temperature in the range of about 23° C. to about 29° C.
Type:
Grant
Filed:
April 10, 2019
Date of Patent:
January 24, 2023
Assignee:
SANOFI-AVENTIS DEUTSCHLAND GMBH
Inventors:
Wolfgang Fiedler, Norbert Pleuss, Bernd Henkel, Manfred Gerken
Abstract: The method for preventing progression to Type II Diabetes includes determining whether a subject possesses a risk variant expression profile demonstrating dysregulation of the IL-33/ST2 axis, and providing an intervention to prevent progression to Type II Diabetes and/or to reverse prediabetes, including modifications of diet and exercise, administration of one or more pharmaceutical compounds, or a combination thereof. The method may be useful to reduce the risk of developing complications associated with Type II Diabetes or prediabetes, such as heart disease, stroke, or obesity. The pharmaceutical compound may be one or more pharmaceuticals capable of reducing circulating cholesterol, reducing blood glucose levels, reducing blood pressure, or a combination thereof.
Abstract: The present disclosure describes novel peptides, including peptides that inhibit the proteolytic activity of insulin-de-grading enzyme (IDE). Also described are cosmetic and pharmaceutical formulations including these peptides, as well as a treatment method aimed at improving the appearance and/or texture of skin and/or promoting wound healing and a method for treating diabetes. The disclosed peptides and formulations are particularly useful for addressing the problem of impaired wound healing in diabetes.
Type:
Grant
Filed:
September 11, 2018
Date of Patent:
January 17, 2023
Assignee:
The Regents of the University of California
Abstract: This invention relates to a cosmetic combination product comprising a first cosmetic composition comprising glucosamine or one of the salts thereof, a second cosmetic composition comprising hyaluronic acid, and possibly a third cosmetic composition comprising collagen, a cosmetic composition comprising glucosamine or one of the salts thereof, hyaluronic acid, and possibly collagen, the uses thereof, in particular for inducing the synthesis of hyaluronic acid and as such combat aging of the skin affecting the keratinocytes and/or the fibroblasts and the dermis, as well as a cosmetic method that implements these combination products and compositions.
Abstract: The present invention relates to peptides for the treatment or prevention of nonalcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH), hepatic steatosis (fatty liver), liver inflammation, cirrhosis, hepatocellular carcinoma or fibrosis, especially liver fibrosis.
Type:
Grant
Filed:
December 14, 2018
Date of Patent:
December 20, 2022
Assignees:
UNIVERSITE DE STRASBOURG, INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE
Abstract: The disclosure is directed in non-limiting embodiments to compounds, compositions, and methods of treating conditions and diseases associated with activation of the gonadotropin GnRH receptor (GnRHR), particularly those involving GnRHR activating autoantibodies (GnRHR AAbs). In one non-limiting embodiment, the disease is Polycystic Ovary Syndrome (PCOS). The therapeutic compounds in at least certain embodiments include peptides which at least partially comprise D-amino acids, such as retro-inverso D-amino acid (RID) peptides, which are able to bind with high affinity to GnRHR AAbs.
Type:
Grant
Filed:
March 4, 2021
Date of Patent:
December 20, 2022
Assignee:
The Board of Regents of the University of Oklahoma
Inventors:
David C. Kem, Xichun Yu, Hongliang Li, LaTasha B. Craig
Abstract: Provided herein are compositions comprising a composite of peptide amphiphiles and biocompatible particles and methods of use thereof for treatment of bone and/or tissue defects. In particular, compositions comprise a slurry paste of a peptide amphiphile nanofiber solution mixed with solid biocompatible particles, and find use in tissue/bone regeneration, growth factor delivery, and/or cell delivery.
Type:
Grant
Filed:
October 14, 2016
Date of Patent:
December 6, 2022
Assignee:
Northwestern University
Inventors:
Mark Trosper McClendon, Samuel I. Stupp, Sungsoo Lee, Erin L. Hsu
Abstract: The present disclosure discloses an antimicrobial peptide Scyreprocin of Scylla paramamosain and a method thereof, wherein an amino acid sequence of the antimicrobial peptide Scyreprocin comprises a sequence shown in SEQ ID NO 01, and the antimicrobial peptide is expressed and purified by using genetic engineering technology. The recombinant antimicrobial peptide Scyreprocin has advantages of wide antimicrobial spectrum, good antimicrobial effect, and rapid germicidal rate, shows great application significance, and has good application in preparation of antimicrobial agents. The recombinant antimicrobial peptide Scyreprocin has no cytotoxicity to mouse hepatocytes AML12, human liver cells L02, and can be safely used for medical treatment or can be used as a feed composition.
Abstract: The present disclosure provides conjugates of polypeptides comprising GLP-1, polypeptide linker and FGF21. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided.
Abstract: The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.
Abstract: An osteogenic composition for implantation at or near a target tissue site beneath the skin is provided, the osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site. In some embodiments, a method is provided for treating a target tissue site in a patient in need of such treatment, the method comprising implanting an osteogenic composition comprising bone morphogenetic protein and a NEMO binding domain peptide, where the NEMO binding domain peptide reduces soft tissue inflammation at or near the target tissue site.
Type:
Grant
Filed:
December 19, 2019
Date of Patent:
November 1, 2022
Assignees:
Cedars-Sinai Medical Center, Warsaw Orthopedic, Inc.
Abstract: The present invention relates to the use of at least one peptide having sequence VRLIVX1VRIX2RR (SEQ ID NO: 1, SEQ ID NO 2, SEQ ID NO 3, SEQ ID NO 4), wherein X1 is selected from A or K and X2 is selected from W and K, as a bactericidal antimicrobial agent against Listeria monocytogenes.
Type:
Grant
Filed:
July 16, 2018
Date of Patent:
October 25, 2022
Assignee:
MATERIAS S.r.l.
Inventors:
Marco Balestrieri, Gianna Palmieri, Gianluca Neglia, Aniello Anastasio, Federico Capuano, Luca De Stefano, Luigi Nicolais
Abstract: The present invention relates to reconstituted high density lipoprotein (rHDL) formulations comprising an apolipoprotein, a lipid and a lyophilization stabilizer. Said formulations have reduced renal toxicity and good long-term stability, especially in lyophilized form.
Abstract: Provided are an ABC transporter peptide inhibitor XH-14C and an application thereof in the treatment of a tumor with multidrug resistance mediated by an ABC transporter. In the application, the peptide inhibitor XH-14C shown in SEQ ID NO: 1 is administered in combination with an ABC transporter substrate chemotherapeutic drug. This disclosure also provides a pharmaceutical composition for treating a tumor with multidrug resistance mediated by the ABC transporter, containing the peptide XH-14C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug.
Type:
Grant
Filed:
May 18, 2021
Date of Patent:
October 4, 2022
Assignee:
HUNAN UNIVERSITY OF SCIENCE AND ENGINEERING
Inventors:
Zuodong Qin, Xiaofang Luo, Luya Feng, Zongcheng Wang
Abstract: A peptide comprised of either a binary or a tertiary peptide, the peptide contains at least 4 amino acids and up to a maximum of 16 amino acids, comprised of 2 or 3 different regions, wherein the binary peptides have 2 different regions and the tertiary peptides have 3 different regions; wherein, the peptide can be cleaved by both an animal gut protease and an insect or nematode gut protease.
Type:
Grant
Filed:
October 6, 2017
Date of Patent:
September 20, 2022
Assignee:
Vestaron Corporation
Inventors:
Alvar R. Carlson, Alexandra M. Haase, Robert M. Kennedy
Abstract: The present disclosure relates to the control of fungal infection of horn-like envelopes covering dorsal and terminal phalanges in humans and animals and related cerebral protrusions in animals as well as keratin comprising material on surfaces of humans and animals. Agents and natural and synthetic formulations and extracts useful for the control of fungal infection of these envelopes and related protrusions and keratin comprising material are also encompassed by the subject disclosure. In an embodiment, the present disclosure teaches the treatment of fungal infection of nails and in particular onychomycosis in humans.
Type:
Grant
Filed:
March 2, 2021
Date of Patent:
September 20, 2022
Assignee:
Hexima Limited
Inventors:
Nicole Louise van der Weerden, Marilyn Anne Anderson